FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085731630> ?p ?o ?g. }

• W2085731630 endingPage "296" @default.
• W2085731630 startingPage "287" @default.
• W2085731630 abstract "Type IIB hyperlipidemia is associated with premature vascular disease, an atherogenic lipoprotein phenotype characterised by elevated levels of triglyceride-rich VLDL and small dense LDL, together with subnormal levels of HDL. The dose-dependent and independent effects of a potent HMGCoA reductase inhibitor, Atorvastatin, at daily doses of 10 and 40 mg, were evaluated on triglyceride-rich lipoprotein subclasses (VLDL-1, VLDL-2 and IDL), on the major LDL subclasses (light LDL, LDL-1+LDL-2, D: 1.019-1.029 g/ml; intermediate LDL, LDL-3, D: 1.029-1.039 g/ml and small dense LDL, LDL-4+LDL+5, D: 1.039-1.063 g/ml), on CETP-mediated cholesteryl ester transfer from HDL to apoB-containing lipoproteins, on phospholipid transfer protein activity and on plasma-mediated cellular cholesterol efflux in patients (n=10) displaying type IIB hyperlipidemia. Plasma concentrations of triglyceride-rich lipoprotein subclasses (TRL: VLDL-1, Sf 60-400; VLDL-2, Sf 20-60 and IDL, Sf 12-20) and of LDL (D: 1.019-1.063 g/ml) were markedly diminished after 6 weeks of statin treatment at 10 mg per day (-31 and -36%, respectively; P<0.002) and by 42 and 51%, respectively at the 40 mg per day dose. Increasing doses of atorvastatin progressively normalised both the quantitative and qualitative features of the LDL subclass profile, in which dense LDL predominated at baseline. Indeed, dense LDL levels were reduced by up to 57% at the 40-mg dose, leading to a shift in the peak of the density profile towards larger, buoyant LDL particles typical of normolipidemic subjects. In addition, marked reduction in numbers of apoB100-containing particle acceptors led to a 30% decrease (P<0.02) in CETP-mediated CE transfer from HDL. Finally, a significant dose-dependent statin-mediated elevation (+15% at 10 mg; P=0.0003 and +35% at 40 mg; P<0.0001 compared to baseline) in the capacity of plasma from type IIB subjects to mediate free cholesterol efflux from Fu5AH hepatoma cells was observed. Moreover, atorvastatin (40 mg per day) significantly increased plasma apoAI levels (+24%; P<0.05), thereby suggesting that this statin enhances production of apoAI and with it, formation of nascent pre-beta HDL particles. Plasma PLTP activity was not affected by either dose of atorvastatin. We conclude that increasing the dose of atorvastatin leads to dose-dependent, preferential and progressive reduction in particle numbers of atherogenic VLDL-2, IDL and dense LDL, and concomitantly, to enhanced cellular cholesterol efflux in type IIB dyslipidemia, thereby diminishing the atherosclerotic burden in subjects characterised by high cardiovascular risk." @default.
• W2085731630 created "2016-06-24" @default.
• W2085731630 creator A5000346574 @default.
• W2085731630 creator A5030510383 @default.
• W2085731630 creator A5037520101 @default.
• W2085731630 creator A5038682682 @default.
• W2085731630 creator A5061775202 @default.
• W2085731630 creator A5073638770 @default.
• W2085731630 creator A5088193518 @default.
• W2085731630 date "2002-08-01" @default.
• W2085731630 modified "2023-10-03" @default.
• W2085731630 title "Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux" @default.
• W2085731630 cites W1967765661 @default.
• W2085731630 cites W1975798465 @default.
• W2085731630 cites W1979582827 @default.
• W2085731630 cites W1988731412 @default.
• W2085731630 cites W1991325639 @default.
• W2085731630 cites W1999369767 @default.
• W2085731630 cites W2008457386 @default.
• W2085731630 cites W2016445095 @default.
• W2085731630 cites W2037406027 @default.
• W2085731630 cites W2038657237 @default.
• W2085731630 cites W2051603643 @default.
• W2085731630 cites W2057674977 @default.
• W2085731630 cites W2078974893 @default.
• W2085731630 cites W2081180316 @default.
• W2085731630 cites W2083392018 @default.
• W2085731630 cites W2087752095 @default.
• W2085731630 cites W2106536809 @default.
• W2085731630 cites W2108483230 @default.
• W2085731630 cites W2109063792 @default.
• W2085731630 cites W2117950105 @default.
• W2085731630 cites W2129850517 @default.
• W2085731630 cites W2152086330 @default.
• W2085731630 cites W2152789823 @default.
• W2085731630 cites W2154447535 @default.
• W2085731630 cites W2155598961 @default.
• W2085731630 cites W2161071771 @default.
• W2085731630 cites W2164941554 @default.
• W2085731630 cites W2185919342 @default.
• W2085731630 cites W2336481777 @default.
• W2085731630 cites W4242270365 @default.
• W2085731630 cites W4361972733 @default.
• W2085731630 doi "https://doi.org/10.1016/s0021-9150(02)00037-0" @default.
• W2085731630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12052475" @default.
• W2085731630 hasPublicationYear "2002" @default.
• W2085731630 type Work @default.
• W2085731630 sameAs 2085731630 @default.
• W2085731630 citedByCount "95" @default.
• W2085731630 countsByYear W20857316302012 @default.
• W2085731630 countsByYear W20857316302013 @default.
• W2085731630 countsByYear W20857316302014 @default.
• W2085731630 countsByYear W20857316302015 @default.
• W2085731630 countsByYear W20857316302016 @default.
• W2085731630 countsByYear W20857316302017 @default.
• W2085731630 countsByYear W20857316302018 @default.
• W2085731630 countsByYear W20857316302019 @default.
• W2085731630 countsByYear W20857316302020 @default.
• W2085731630 countsByYear W20857316302021 @default.
• W2085731630 countsByYear W20857316302022 @default.
• W2085731630 crossrefType "journal-article" @default.
• W2085731630 hasAuthorship W2085731630A5000346574 @default.
• W2085731630 hasAuthorship W2085731630A5030510383 @default.
• W2085731630 hasAuthorship W2085731630A5037520101 @default.
• W2085731630 hasAuthorship W2085731630A5038682682 @default.
• W2085731630 hasAuthorship W2085731630A5061775202 @default.
• W2085731630 hasAuthorship W2085731630A5073638770 @default.
• W2085731630 hasAuthorship W2085731630A5088193518 @default.
• W2085731630 hasConcept C104950815 @default.
• W2085731630 hasConcept C126322002 @default.
• W2085731630 hasConcept C134018914 @default.
• W2085731630 hasConcept C134651460 @default.
• W2085731630 hasConcept C181199279 @default.
• W2085731630 hasConcept C185592680 @default.
• W2085731630 hasConcept C2776448209 @default.
• W2085731630 hasConcept C2777482532 @default.
• W2085731630 hasConcept C2778163477 @default.
• W2085731630 hasConcept C2778913445 @default.
• W2085731630 hasConcept C2779091943 @default.
• W2085731630 hasConcept C2779620165 @default.
• W2085731630 hasConcept C2780072125 @default.
• W2085731630 hasConcept C55493867 @default.
• W2085731630 hasConcept C555293320 @default.
• W2085731630 hasConcept C62746215 @default.
• W2085731630 hasConcept C71924100 @default.
• W2085731630 hasConcept C8004288 @default.
• W2085731630 hasConcept C8243546 @default.
• W2085731630 hasConceptScore W2085731630C104950815 @default.
• W2085731630 hasConceptScore W2085731630C126322002 @default.
• W2085731630 hasConceptScore W2085731630C134018914 @default.
• W2085731630 hasConceptScore W2085731630C134651460 @default.
• W2085731630 hasConceptScore W2085731630C181199279 @default.
• W2085731630 hasConceptScore W2085731630C185592680 @default.
• W2085731630 hasConceptScore W2085731630C2776448209 @default.
• W2085731630 hasConceptScore W2085731630C2777482532 @default.
• W2085731630 hasConceptScore W2085731630C2778163477 @default.
• W2085731630 hasConceptScore W2085731630C2778913445 @default.
• W2085731630 hasConceptScore W2085731630C2779091943 @default.

• next